In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...

A study found that a diabetes treatment DPP-4 inhibitor prevents Parkinson's disease from progressing. A research team led by Professor Jeong Seung-ho of Yongin Severance Hospital, Kim Yeon-joo of ...

A large McGill University study has found that two classes of medications commonly prescribed for type 2 diabetes, both ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

CSPC Pharmaceutical Group Ltd. on Jan. 13 gained the National Medical Products Administration’s approval of Shanzeping (prusogliptin tablets; DBPR-108) as a novel oral dipeptidyl peptidase-IV (DPP-4) ...

With regards to his pioglitazone use, he had no history of heart failure, and his ALT level was acceptable at the time of discharge at 25 U/L. Signs and symptoms of heart failure were reviewed with ...